Trial Profile

A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mavrilimumab (Primary) ; Prednisone
Indications Giant cell arteritis
Focus Proof of concept; Therapeutic Use
Sponsors Kiniksa Pharmaceuticals

Most Recent Events

09 Mar 2022 Results published in the Annals of the Rheumatic Diseases
09 Nov 2021 Results of post hoc analysis assessing the CRP and ESR levels from randomization through Wk 26 in patients with and without relapse by treatment arm presented at the ACR Convergence 2021
01 Nov 2021 According to a Kiniksa Pharmaceuticals media release, data from this trial will be presented at the upcoming American College of Rheumatology (ACR) Convergence 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com